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Nuclear factor-jB (NF-jB) is an inducible nuclear transcription factor regulating a range of cellular processes. An
imbalance of the DNA binding activity of NF-jB may, therefore, be part of the pathophysiological mechanisms in
psoriasis. The purpose of this study was to determine the NF-jB DNA binding activity in psoriatic skin using three
different jB sites and to determine how DNA binding activity was modulated by the anti-psoriatic drug calcipotriol.
By electrophoretic mobility shift assay, we demonstrated that the NF-jB DNA binding to the p53 jB site was
decreased, whereas the NF-jB DNA binding to the interleukin-8 (IL-8) jB site was increased in lesional psoriatic
skin compared with non-lesional psoriatic skin. No regulation was seen on the NF-jB DNA binding to the major
histocompatibility complex class I jB site. These changes were paralleled by a similar decrease in p53 expression
and an increase in IL-8 expression in involved psoriatic skin compared with uninvolved skin as determined by
quantitative RT-PCR. The alteration in NF-jB DNA binding activity was neither accompanied by any change in the
expression of the inhibitor jB (IjB) kinases, IKKa, IKKb, and IKKc nor in the expression of the NF-jB inhibitor
proteins, IjBa and IjBb. Immunoﬂuorescence analysis revealed that p65 was sequestered in the cytoplasm of
keratinocytes, whereas p50 exhibited a cytoplasmic as well as a nuclear localization. Interestingly, this distribution
of p50 and p65 was similar in lesional and non-lesional psoriatic skin. Topical application of calcipotriol to lesional
psoriatic skin for 4 d resulted in increased NF-jB binding to the p53 jB site and decreased NF-jB binding to the IL-8
jB site. Taken together, our data demonstrate that the NF-jB DNA binding activity is regulated in a specific manner
in psoriatic skin depending on the jB sites investigated, and that topical treatment of psoriatic skin normalizes the
abnormal NF-jB binding activity seen in lesional psoriatic skin.
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Psoriasis is an inflammatory skin disease characterized by
hyperproliferation, altered maturation of the epidermis, and
accumulation of many inflammatory mediators in the lesio-
nal skin (Hammarstrom et al, 1975; Stern, 1997; Chamian
and Krueger, 2004). Cytokines and inflammatory mediators
contribute to the establishment and maintenance of the
pathological phenotype of psoriasis lesions by directly
modulating keratinocyte differentiation and proliferation
(Terui et al, 2000).
The transcription factor, nuclear factor-kB (NF-kB), is
believed to play a pivotal role in immune and inflammatory
responses through the regulation of genes encoding pro-
inflammatory cytokines, adhesion molecules, chemokines,
and growth factors (Karin and Ben Neriah, 2000; Tak and
Firestein, 2001). The active form of NF-kB is a dimer formed
by members of the NF-kB/Rel family of proteins, consisting
of p50 (NF-kB1), p52 (NF-kB2), p65 (RelA), c-Rel, and
RelB (Liou and Baltimore, 1993; Baeuerle and Henkel,
1994). In resting cells, NF-kB is retained in the cytoplasm as
an inactive complex with the inhibitor kB (IkB), which masks
the nuclear localization sequences of NF-kB (Baldwin,
1996). Cellular stimulation with various agents leads to
phosphorylation, ubiquitination, and subsequent degrada-
tion of IkB, thereby unmasking the nuclear localization se-
quence of NF-kB. This leaves NF-kB free to translocate to
the nucleus, where it binds to kB sites in specific target
genes (Pahl, 1999). The phosphorylation of IkB is an im-
portant step in the pathway leading to NF-kB activation,
and this step is catalyzed by the IkB kinase (IKK) complex,
consisting of IKKa, IKKb, and IKKg (also called NEMO)
(Ghosh and Karin, 2002).
In a recent study, we examined the localization of NF-kB
in non-lesional and lesional psoriatic skin by immunohisto-
chemistry. In non-lesional psoriatic skin, both p50 and p65
were sequestered in the cytoplasm, whereas p50, but not
p65, localized to the nuclei. This distribution was maintained
in lesional psoriatic skin (Westergaard et al, 2003).
Abbreviations: EMSA, electrophoretic mobility shift assay; IkB, in-
hibitor kB; IKK, IkB kinase; IL-8, interleukin 8; MHC-I, major his-
tocompatibility complex class I; NF-kB, nuclear factor kB
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Once activated, NF-kB regulates a variety of genes
containing the consensus sequence G/(T)GGRNNYYC/(T)C,
referred to as a kB site (T¼ thymine, G¼guanine, C¼ cyto-
sine, R¼purine, Y¼pyrimidine, N¼ any base). A number of
closely related kB sites have been discovered (Pei et al,
1999; Schottelius et al, 1999; Kim et al, 2000) and these
minor differences may in part determine whether or not NF-
kB activation leads to transcription of the particular gene.
Thus, the purpose of this study was to examine whether
the NF-kB DNA binding activity was modulated in psoriatic
skin. This was done by using three synthetic oligonucleo-
tides comprising either the p53, the interleukin-8 (IL-8), or
the major histocompatibility complex class I (MHC-I) kB
binding site. p53 is a tumor suppressor protein involved in
the control of cell growth and apoptosis, IL-8 is a cytokine
involved in pro-inflammatory processes, whereas MHC-I is
a protein located on the cell surface and involved in cell
adhesion. Hence, p53, IL-8, and MHC-I have their unique
but different role to play in the cell.
Results
Inverse regulation of NF-jB DNA binding to the p53 and
IL-8 jB response element in lesional psoriatic skin To
examine NF-kB DNA binding to the p53, the IL-8, and the
MHC-I kB sites, the nuclear fraction from keratome biopsies
obtained from lesional and non-lesional psoriatic skin was
incubated with a 32P-labelled oligonucleotide comprising
the kB site from either the p53, the IL-8, or the MHC-I pro-
moter. In extracts from lesional psoriatic skin, the level of
NF-kB DNA binding activity to the p53 kB site was signif-
icantly reduced compared with extracts from non-lesional
psoriatic skin from the same patient (4.5-fold, po0.05) (Fig
1a). In contrast, using a 32P-labelled oligonucleotide com-
prising the kB site from the IL-8 promoter, the NF-kB DNA
binding activity was significantly increased in lesional
psoriatic skin compared with non-lesional psoriatic skin
(3.2-fold, po0.05) (Fig 1b). Finally, using a labelled oligonuc-
leotide comprising the kB site from the MHC-I promoter, the
NF-kB binding activity in lesional compared with non-les-
ional psoriatic skin was not regulated (Fig 1c). This was
observed for each of the five patients examined.
Characterization of the NF-jB DNA binding complex To
further characterize the NF-kB complex binding to the p53
and IL-8 kB site, respectively, electrophoretic mobility shift
assay (EMSA) were carried out in the presence of super-
shifting antibodies directed against the different NF-kB/Rel
proteins. Using nuclear extracts from both non-lesional and
lesional skin, the presence of anti-p50 antibody resulted in a
complete shift of the p53 kB complex, whereas the anti-p65
antibody only partly shifted the complex. No supershift was
observed with antibodies against p52, c-Rel, or RelB
(Fig 2a). Using the IL-8 kB site for EMSA, increased bind-
ing with extracts from lesional skin was observed as re-
ported above. Interestingly, addition of the anti-p50
antibody significantly decreased complex formation with
extracts from lesional skin, whereas addition of the anti-p65
antibody partly supershifted the complex with extracts from
both non-lesional and lesional psoriatic skin (Fig 2b). As for
Figure1
Nuclear factor-jB (NF-jB) DNA binding activity in lesional and non-
lesional psoriatic skin. Keratome biopsies were taken from patients
with psoriasis vulgaris. The biopsies were homogenized and the nu-
clear fraction isolated and incubated with a labelled oligonucleotide
identical to either the kB site from the p53 promoter (a), the interleukin-
8 (IL-8) promoter (b), or the major histocompatibility complex class I
(MHC-I) promoter (c). The NF-kB binding activity was then determined
by electrophoretic mobility shift assay.
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the p53 kB site, no supershifts were observed with anti-p52,
anti-c-Rel, and anti-RelB antibodies. These results indicate
that the NF-kB complexes associated with the p53 and IL-8
kB sites are dominated by p50, and only to a minor extent
contain p65. But the different behavior of the complexes
formed on the p53 and the IL-8 kB site, respectively, in
response to addition of the anti-p50 antibody suggests
structural differences between the two types of complexes.
To validate the functionality of the anti-p65 antibody in su-
pershift analyses, we prepared a nuclear extract from ker-
atinocytes treated with or without IL-1b. Cultured normal
human keratinocytes were stimulated with IL-1b (10 ng per
mL) for 15 min and the nuclear fraction was isolated. EMSA
was performed in the absence or presence of anti-p50 and
anti-p65 antibodies. The presence of both anti-p50 and
anti-p65 clearly resulted in a shifted complex (Fig 2c).
Treatment of psoriatic skin with calcipotriol leads to a
normalization of the NF-jB DNA binding activity The vi-
tamin D analogue calcipotriol is used in the treatment of
Figure 2
Characterization of the nuclear factor-jB (NF-jB) binding complex. Supershift analysis of the NF-kB dimer in lesional and non-lesional psoriatic
skin was carried out. Antibodies directed against the indicated NF-kB/Rel proteins were added to the incubation mixture 10 min prior to the addition
of the labelled oligonucleotide identical to either the p53 kB site (a) or the interleukin-8 (IL-8) kB site (b). Cultured human keratinocytes were
stimulated with IL-1b (10 ng per mL) for 15 min before the nuclear fraction was isolated and analyzed by electrophoretic mobility shift assay (c).
Antibodies directed against p65 and p50 were added to the incubation mixture 10 min prior to the addition of the labelled oligonucleotide identical to
the p53 kB site.
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psoriasis (Kragballe, 1992). To examine whether treatment
of psoriatic skin with calcipotriol modulates the NF-kB DNA
binding activity, nuclear extracts from paired biopsies of
lesional psoriatic skin treated with or without calcipotriol
under occlusion for 4 d were incubated with either the 32P-
labelled oligonucleotide comprising the IL-8 kB site or the
32P-labelled oligonucleotide comprising the p53 kB site.
NF-kB binding to the p53 kB site was significantly increased
after treatment with calcipotriol when compared with vehi-
cle-treated skin (2.1-fold, po0.05) (Fig 3a), whereas NF-kB
binding to the IL-8 kB site was significantly reduced con-
sistently in all three patients investigated (3.1-fold, po0.05)
(Fig 3b).
p53 and IL-8 mRNA expression in psoriatic skin To ex-
amine whether the decreased NF-kB binding to the p53 kB
site and the increased NF-kB binding to the IL-8 kB site
seen in psoriatic skin were paralleled by decreased p53 and
increased IL-8 mRNA expression, quantitative RT-PCR was
carried out. The IL-8 mRNA expression was significantly
augmented in lesional psoriatic skin, exhibiting an approx-
imately 4-fold increase compared with non-lesional psoria-
tic skin (Fig 4a). In contrast, the p53 mRNA expression was
slightly decreased in lesional psoriatic skin compared with
non-lesional psoriatic skin, although this was not statisti-
cally significant (Fig 4a). The increased IL-8 mRNA expres-
sion seen in psoriatic skin was paralleled by an increased
IL-8 protein level as demonstrated by western blotting
(Fig 4b). In addition, the decreased p53 mRNA expression
was paralleled by decreased p53 protein content in psoria-
tic skin, although this was not significant (Fig 4c). Equal
protein loading was confirmed by incubation with an anti-
transcription factor II B (TFIIB) or anti-b-actin antibody.
Analysis of NF-jB/Rel expression by quantitative RT-
PCR and western blotting An analysis of NF-kB/Rel
mRNA expression of p50, p65, RelB, p52, and c-Rel NF-
kB subunits was carried out in lesional psoriatic skin and
compared with non-lesional psoriatic skin. Real-time RT-
PCR analysis of RNA from lesional and non-lesional psoria-
tic skin biopsies was performed. Using expression of the
TATA binding protein for normalization, expression of all the
NF-kB/Rel subunits examined tended to be increased in
lesional compared with non-lesional psoriatic skin (Fig 5a).
The biological significance of this increase, however, is un-
certain because of large patient-to-patient variations, and
western blotting revealed no statistically significant differ-
ences in the expression of the NF-kB family member be-
tween non-lesional and lesional psoriatic skin. The p52 and
c-Rel subunits could not be detected by western blotting
(data not shown). Equal protein loading was confirmed by
assessing the protein level of TFIIB (Fig 5b).
Immunoﬂuorescence localization of p65 and p50 in
psoriatic skin To examine the localization of the NF-kB
subunits p50 and p65 in lesional and non-lesional psoriatic
skin, immunofluorescence analysis was carried out. We
found that p50 and p65 were sequestered in the cytoplasm,
whereas p50, but not p65, also localized to the nuclei. The
localization patterns for p50 and p65 were similar in lesional
and non-lesional psoriatic skin (Fig 6). These results were
conducted on biopsies from three different patients.
Analysis of IKK and IjB protein levels To examine
whether the altered NF-kB DNA binding activity seen in
psoriatic lesions was because of a regulation of the IKK or
the IkB proteins, whole-cell extracts from lesional and non-
lesional psoriatic skin were isolated and western blot anal-
ysis was performed. No alteration in the protein contents of
IKKa, b, and g was found in lesional psoriatic skin compared
with non-lesional skin (Fig 7a). Also, no regulation in the
phosphorylated form of IKKa/b between lesional and non-
Figure 3
Nuclear factor-jB (NF-jB)
DNA binding activity in les-
ional psoriatic skin treated
with calcipotriol. Nuclear
extracts were isolated from
lesional psoriatic skin treated
with either calcipotriol or ve-
hicle for 4 d. The NF-kB DNA
binding activity to the p53 kB
site (a) and the interleukin-8
(IL-8) kB site (b) were then
assayed by electrophoretic
mobility shift assay.
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lesional psoriatic skin was found (Fig 7b). Examination of the
protein levels of IkBa and IkBb showed no differences be-
tween lesional and non-lesional psoriatic skin (Fig 7c).
Discussion
Members of the NF-kB/Rel family of transcription factors
are key regulators of cellular growth and immune and in-
flammatory responses (Karin and Ben Neriah, 2000; Ghosh
and Karin, 2002). Numerous studies have demonstrated
that the NF-kB binding activity is altered in inflammatory
diseases such as rheumatoid arthritis and Crohn’s disease
and it is believed that the altered NF-kB activity plays an
important role in the inflammatory processes (Asahara et al,
1995; Ellis et al, 1997, 1998; Makarov, 2001). In most stud-
ies analyzing NF-kB binding activity, however, only a single
NF-kB binding site was analyzed.
In this study, we demonstrate that the NF-kB DNA bind-
ing to the IL-8 kB site was increased in lesional psoriatic
skin compared with non-lesional psoriatic skin. Interesting-
ly, using an oligonucleotide comprising the kB site of the
p53 promoter, we found that the NF-kB DNA binding was
reduced in lesional psoriatic skin compared with non-les-
ional psoriatic skin, whereas no regulation of NF-kB DNA
binding to the MHC-I kB site was found. These results were
paralleled by an increased IL-8 mRNA and protein expres-
sion together with a decreased p53 mRNA and protein
expression in lesional psoriatic skin compared with non-
lesional psoriatic skin, which has also been demonstrated
by others (Gearing et al, 1990; Michel et al, 1996; Jiang et al,
2001). IL-8 is a pro-inflammatory cytokine believed to be
involved in the pathogenesis of a number of inflammatory
diseases including psoriasis (Larsen et al, 1991; Kunsch
et al, 1994). The fact that the NF-kB DNA binding to the IL-8
kB site is increased and the fact that the NF-kB binding to
the p53 kB site is decreased, whereas the NF-kB binding to
the MHC-I kB site is unchanged, indicates that NF-kB is
able to distinguish between different genes and thereby
activate or repress specific genes whereas others are not
regulated.
Vitamin D analogues are used in the treatment of pso-
riasis (Kragballe, 1992; Lamba and Lebwohl, 2001). The
anti-psoriatic effects of vitamin D have mainly been as-
cribed to its pro-differentiating and anti-proliferative effects
on the keratinocytes (Smith et al, 1986). But vitamin D is
also known to modulate inflammation leading to inhibition of
IL-8 and stimulation of IL-10 in psoriatic skin (Kang et al,
1998). These effects may in part be because of a regulation
of NF-kB. Recently, we demonstrated that vitamin D inhib-
ited the IL-1a-induced NF-kB binding activity to the IL-8 kB
response element in cultured normal human keratinocytes
through an increase in IkBa expression (Riis et al, 2004).
Furthermore, previous studies using kB sites comprising
either the IL-6 or the IL-8 promoter region, respectively,
have demonstrated that vitamin D inhibits NF-kB activity in
both activated human lymphocytes (Yu et al, 1995) and ac-
tivated human fibroblasts (Harant et al, 1998), This is in
accordance with our finding that topical treatment of the
psoriatic skin with the vitamin D analogue, calcipotriol, for 4
d, resulted in decreased NF-kB binding to the IL-8 kB site
and increased NF-kB binding to the p53 kB site.
NF-kB has recently been shown to play different roles in
different phases of an inflammation (Lawrence et al, 2001).
During the onset of inflammation, NF-kB activation is as-
sociated with pro-inflammatory gene expression, whereas
Figure 4
p53 and interleukin-8 (IL-8) expression in psoriatic skin. (a) Real-time RT-PCR was
carried out on RNA from six paired biopsies from lesional and non-lesional psoriatic skin.
Numbers above 1 indicate an increased expression, whereas numbers below 1 indicate a
decreased expression in lesional compared with non-lesional psoriatic skin. (b, c) Whole-
cell extracts from psoriatic skin biopsies were isolated and then the IL-8 (b) and p53 (c)
protein level was determined by western blotting using antibodies directed against either
the IL-8 or the p53 protein. Equal loading was confirmed by incubation with an anti-
transcription factor II B (TFIIB) or anti-b-actin antibody.
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NF-kB activation during the resolution of inflammation is
associated with the expression of anti-inflammatory genes
(induction of p53) and the induction of apoptosis. During the
onset of inflammation, the dominating NF-kB complex was
c-Rel/p50, whereas there was a shift to a predominance of
p50/p50 at the resolution of inflammation (Lawrence et al,
2001). The inflammation occurring in psoriasis is associated
with increased IL-8 and decreased p53 expression. It is
therefore possible that the shift in NF-kB subunit expression
leading to the resolution of inflammation does not take
place in psoriasis. This might be an important mechanism
whereby inflammation is maintained in psoriasis. Calcipo-
triol probably mediates its anti-psoriatic effects by increas-
ing NF-kB binding activity to the p53 kB site and thereby
shifting the disease from an ongoing inflammation to a res-
olution of inflammation.
Because NF-kB is a dimer formed by p50, p52, p65, c-
Rel, or RelB, we hypothesized that a differential expression
of these subunits could explain the differential regulation of
IL-8 and p53 in psoriasis. Using quantitative RT-PCR, all NF-
kB/Rel subunits were detected in psoriatic skin and ex-
pression at the mRNA level tended to be slightly increased
in lesional psoriatic skin compared with non-lesional skin. In
accordance with previous immunohistochemical analyses
(Takao et al, 2003), however, only p50, p65, and RelB could
be detected by western blotting, and no alterations in ex-
pression between lesional and non-lesional skin were ob-
served at the protein level. Considering that the NF-kB p65
subunit has been suggested to be one of the major com-
ponents of the NF-kB complexes binding to the IL-8 kB site
(Kunsch and Rosen, 1993) and the fact that the NF-kB DNA
binding activity to the IL-8 kB site was increased in lesional
psoriatic skin, it is interesting that no nuclear localization of
p65 could be detected in lesional psoriatic skin as demon-
strated by immunofluorescence analysis. This has also
been demonstrated in another study by our group using
immunohistochemical analyses (Westergaard et al, 2003).
The lack of detection, however, may well relate to problems
of sensitivity since the EMSA results clearly show that minor
amounts of p65 are present in the NF-kB complexes formed
on the p53 as well as the IL-8 kB recognition sites.
Activation of NF-kB is regulated by its cytoplasmic in-
hibitor the IkB, which again is phosphorylated by the IKK
(Karin and Ben Neriah, 2000). As demonstrated in this study,
the imbalance in the NF-kB activity in binding to the IL-8
and p53 kB site seen in psoriatic skin was not because of
altered expression or activation of the IKK, nor to alterations
of IkBa or IkBb. In a recent study, however, it was demon-
strated that the MAP-kinase p38 is involved in the phos-
phorylation of histone H3, and it was suggested that this
Figure 5
Expression of the nuclear factor-jB (NF-jB)/Rel subunits in lesio-
nal psoriatic skin. (a) The mRNA expression levels of the NF-kB/Rel
subunits in lesional and non-lesional psoriatic skin were determined by
real-time RT-PCR. Numbers above 1 indicate increased expression in
lesional compared with non-lesional psoriatic skin. (b) Whole-cell pro-
tein extracts were prepared from lesional and non-lesional psoriatic
skin, and separated by SDS-PAGE on an 8%–16% gradient gel. After
electroblotting, the separated proteins were probed with anti-p50, anti-
p65, and anti-RelB antibodies. Equal loading was confirmed by incu-
bation with an anti-TFIIB antibody.
Figure6
 100 LSM micrographs of human non-lesional and lesional
psoriatic skin biopsies. Paired samples from involved (þ Inv) and
non-involved (Inv) psoriatic skin are presented. Insets show details
blown up from  250 LSM micrographs. Red (SYTOX DNA stain)
demonstrates the location of nuclei, green (Alexa488-conjugated an-
tibody) demonstrates the location of nuclear factor-kB (NF-kB), and
yellow indicates co-localization. These results were conducted on bi-
opsies from three different patients.
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p38-dependent histone H3 phosphorylation may mark pro-
moters for increased NF-kB recruitment (Saccani et al,
2002). We have found that p38 is significantly activated in
lesional psoriatic skin (Johansen et al, 2004b) and it is
therefore possible that a p38-dependent mechanism can
explain the increased IL-8 kB binding.
Taken together, our data demonstrate that the NF-kB
DNA binding activity is regulated in a specific manner in
psoriatic skin depending on the kB sites investigated, and
that topical treatment of psoriatic skin normalizes the ab-
normal NF-kB binding activity seen in lesional psoriatic skin.
It is possible that the imbalance in NF-kB binding activity
seen in psoriatic skin is caused by a p38-dependent mech-
anism. Further experiments, however, need to be carried
out to clarify this.
Materials and Methods
Materials Gel shift binding 5  buffer, T4 polynucleotide kinase,
and T4 polynucleotide kinase 10  buffer were obtained from
Promega (Madison, Wisconsin). [g-32P]ATP, enhanced chemilumi-
nescence detection system (ECL), and nick spin columns Se-
phadex G-50 fine DNA grade were provided by Amersham
Biosciences (Uppsala, Sweden). Antibodies against TFIIB, IkBa,
IkBb, p50, p65, p52, RelB, c-Rel, IKKa, IKKb, IKKg, p53, and the
phosphorylated forms of IKKa/b were purchased from Santa Cruz
Biotechnology (Santa Cruz, California).
Cell cultures Normal adult human keratinocytes were obtained by
trypsinization of skin samples from patients undergoing plastic
surgery as previously described (Kragballe et al, 1985). First-pas-
sage keratinocytes were grown in KSFM. Twenty four hours before
IL-1b stimulation (10 ng per mL), the medium was changed to
keratinocyte basal medium (the same as KSFM but without growth
factors) in which the cells were stimulated. Cells were grown at
371C and 5% CO2 in an incubator.
Biopsies Keratome biopsies from lesional and non-lesional
plaque-type psoriatic skin and lesional plaque-type psoriatic skin
treated under occlusion with calcipotriol ointment or vehicle for 4 d
in patients with psoriasis vulgaris were taken from the center of a
plaque from patients with moderate-to-severe chronic stable
plaque psoriasis from either the upper or lower extremities. For
each patient, biopsies were taken from only one anatomical site.
Biopsies were taken as paired samples and biopsies from non-
lesional psoriatic skin were taken from the same body region as
biopsies from lesional psoriatic skin at a distance of at least 5 cm
from a lesional plaque. This study was conducted according to the
Declaration of Helsinki Principles. The local ethical committee of
Aarhus approved all described studies. Informed consent was ob-
tained from each patient.
EMSA Gel shift assays were performed as described previous-
ly (Johansen et al, 2000). Oligonucleotides used for the gel
shift analysis were: hp53, 50-GGGATTGGGGTTTTCCCCTCCC-30,
containing the kB site from the p53 promoter, hIL-8, 50-AA-
TCGTGGAATTTCCTCTGACA-30, containing the kB site from the
IL-8 promoter, and hMHC-I, 50-GCGTTGGGGATTCCCCACTCCC-
30, containing the kB site from the MHC-I promoter. The oligonuc-
leotides were labelled by T4 polynucleotide kinase. Labelled
oligonucleotides were purified on a Nick Spin column (G-50,
Pharmacia, Uppsala, Sweden).
Isolation of the nuclear fraction from skin biopsies The kera-
tome biopsies were homogenized in 5 mL homogenization buffer
(10 mM Hepes, pH 7.6, 25 mM KCl, 0.15 spermine, 0.5 mM
Figure 7
Analysis of IjB kinase (IKK)a/b/c,
IjBa, and IjBb in psoriatic skin.
(a, b, c) Whole-cell extracts were
prepared from lesional and non-les-
ional psoriatic skin. The proteins
were separated on an 8%–16%
gradient gel and blotted on a nitro-
cellulose membrane. After blotting,
the membrane was probed with the
indicated antibodies. Equal loading
was confirmed by incubation with
an anti-TFIIB antibody.
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spermidine, 1 mM EDTA, 2 M sucrose, and 10% glycerol). The
following reagents were added to 25 mL homogenization buffer
prior to use: 25 mL of 100 mM PMSF; 125 mL of leucine thiol (5 mg
per mL); 50 mL of pepstatin (1 mg per mL); and 125 mL of leupeptin
(1 mg per mL). The homogenate was then centrifuged at
100,000  g for 1 h at 41C. The pellet was washed two times with
2 mL Dignam’s buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, and 0.5 mM DTT), before it was resuspended in 100 mL
extraction buffer (20 mM Hepes, pH 7.8, 520 mM NaCl, 0.1 mM
EDTA, 25% glycerol, 1.5 mM MgCl2, 0.5 mM PMSF, 0.5 mM DTT,
0.2% nonident P-40, leupeptin 1 mg per mL, pepstatin 1 mg per
mL). The samples were left on ice for 1 h and then centrifuged at
150,000  g for 15 min. The supernatant constituted the nuclear
extract. Protein concentration was determined as previously
described by Bradford (1976), with bovine serum albumin as
standard.
Western blotting Whole-cell extracts were prepared using the
TRIZOL reagent according to the recommendation of the manu-
facturer (GIBCO BRL/Life Technologies, Gaithersburg, Maryland).
Thirty micrograms of whole-cell protein extracts in sample buffer
(50 mM Tris-HCl, 10% glycerol, 2.5% SDS, 10 mM DTE, 10 mM b-
glycerophosphate, 10 mM NaF, 100 mM Na orthovanadate, 7 M
urea) were separated by SDS-PAGE in 10% gels and blotted onto a
nitrocellulose membrane. Membranes were incubated with either
anti-IkBa, anti-IkBb, anti-p65, anti-p50, anti-RelB, anti-IKKa, anti-
IKKb, anti-IKKg, anti-phospho-IKKa/b, or anti-TFIIB antibodies and
detected with anti-rabbit IgG-HRP (Dako-Cytomation, Glostrup,
Denmark) in a standard ECL reaction (Amersham Biosciences)
according to the manufacturer’s instructions.
Quantitative RT-PCR Total RNA was isolated from human psoria-
tic biopsies (TRI reagent, Sigma-Aldrich, St. Louis, Missouri) and
reverse transcribed (M-MLV reverse transcriptase kit, Life Tech-
nologies) with random hexamers (PdN6, Pharmacia). cDNA was
amplified on the ABI Prism 7700 real-time instrument (Applied
Biosystems, Foster City, California) using Universal SYBR green
Master Mix (Applied Biosystems). The primers were: IL-8 (FP: 50-
CCCAGTCCTTTGGCTTCATC; RP: GGGCCTT AAACAGCGTACG),
P21 (FP: 50-CGACTGTGATGCGCTAATGG; RP: CCTCTTGGAGAA-
GATCAGCC), CycD1 (FP: 50-CGTGGCCTCTAAGATGAAGGA; RP:
ACTTGAGCTTGTTCACCAGGAG), 18SrRNA (FP: 50-TCTAGATAA-
CCTCGGGCCGA; RP: 50-ACGGCGACTACCAT CGAAAG), Bcl-3
(FP: 50-GTCAACCCTTCTGGAAACTGTG; RP: 50-TGCTTCTGTGC-
AAATCCTGG), p50/p105 (FP: AGCAGGAAGATG TGGTGGAGGA;
RP: 50-TATCATGTCCTTCTTTGGCAGCTA), c-Rel (FP: 50-TGGGAGA-
GACTGATAATCCAAGAC; RP: 50-GATGGAGCT GTCTCAAGTCT-
CTTG), p52/p100 (FP: 50-CCCTACCTCTGATAGC GACTC; RP: 50-
AGCTGCTTCGGGTGTCCTTC), RelB (FP: 50-GGGCCGTGGTT-
GGGGAGA; RP: 50-GTACGAGTCCAGTGTCAG TGGT), and p65
(FP: 50-CCTGCTCCAGCCATGGTATCA; RP: 50-AGGAGGGCCT-
GGGGCTAG).
Immunoﬂuorescence Approximately 4 mm thick microtome sam-
ples from frozen psoriasis punch biopsies were fixed in ice-cold
4% formaldehyde for 10 min, neutralized in 50 mM NH4Cl for 5 min
at room temperature (RT), and permeabilized in 70% EtOH at
201C for a minimum of 15 min. After 30 min incubation in blocking
solution (3% bovine serum albumin in neutral phosphate-buffered
saline), samples were incubated in blocking solution with p65 or
p50 antibody at RT, repetitively, washed and incubated with Ale-
xa488-conjugated secondary antibody (Molecular Probes, Eugene,
Oregon) for 45 min at RT, and washed again. Samples were then
incubated in SYTOX Orange (Molecular Probes) in 100 mM NaCl
for 5 min at RT, washed, and mounted with fluorescent mounting
medium (DakoCytomation, Glostrup, Denmark). Micrographs were
obtained by a multitracking laser scanning microscopy with the
LSM 510 Meta (Zeiss, OberKochen, Germany).
Statistics Results were expressed as mean  standard devi-
ation (SD). Statistical significance (po0.05) was assessed by Stu-
dent’s t test. To test for normal distribution, a probability test was
conducted.
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